Status:
COMPLETED
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Lead Sponsor:
Vascular Biogenics Ltd. operating as VBL Therapeutics
Conditions:
Differential Thyroid Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed advanced DTC (papillary, follicular, Hurthle cell);
- Absence of sensitivity to therapeutic radioiodine;
- Measurable disease, defined as at least one non-bony lesion that can be accurately measured in at least one dimension as confirmed with spiral CT scan
- Life expectancy \>3 months; ECOG performance status (PS) 0, 1, or 2; Karnofsky performance status of ≥60%;
- Subjects with a normal/acceptable hematological profile
- Subjects with adequate renal function
Exclusion
- Presence of any of the following:
- Radiotherapy or chemotherapy \<4 weeks prior to baseline visit; (Concurrent and/or prior therapy with octreotide will be allowed, provided tumor progression on this therapy has been demonstrated; Concurrent and/or prior therapy with biphosphonates will be allowed)
- Radiotherapy to ≥25% of bone marrow;
- Major surgery \<4 weeks prior to baseline visit;
- Any other ongoing investigational agents within 4 weeks before dosing;
- Subjects who suffered from an acute cardiac event within the last 12 months, including myocardial infarction, cardiac arrythmia, admission for unstable angina, cardiac angioplasty, or stenting;
- QTc prolongation (defined as QTc interval ≥500 msecs) or other significant ECG abnormalities (e.g. frequent ventricular ectopy, evidence of ongoing myocardial ischemia);
- Subjects with active vascular disease, either myocardial or peripheral;
- Subjects with proliferative and/or vascular retinopathy;
- Subjects with known active liver disease (alcoholic, drug/toxin induced, genetic, or autoimmune) other than related to tumor metastases;
- Subjects with known CNS metastatic disease (Exception: Subjects with treated CNS metastases stable by radiographic examinations \>6 months after definitive therapy administered, are eligible);
- Subjects testing positive to one of the following viruses: HIV, HBV or HCV;
- Any of the following conditions:
- Serious or non-healing wound, ulcer, or bone fracture;
- History of abdominal fistula, gastro-intestinal perforation, active diverticulitis, intra-abdominal abscess or gastro-intestinal tract bleeding within 6 months of dosing;
- Any history of cerebrovascular accident (CVA) within 6 months of dosing;
- Current use of therapeutic warfarin (Note: Low molecular weight heparin and prophylactic low-dose warfarin \[INR\<1.2 X ULN\] are permitted);
- History of bleeding disorder, including subjects with hemophilia, disseminated intravascular coagulation (DIC), or any other abnormality of coagulation potentially predisposing subjects to bleeding;
- Poorly controlled depression or anxiety disorder, or recent (within the previous 6 months) suicidal ideation;
- Subjects with an ongoing requirement for immunosuppressive treatment, including the use of glucocorticoids or cyclosporin, or with a history of chronic use of any such medication within the last 4 weeks before dosing;
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT01229865
Start Date
December 1 2010
End Date
June 1 2016
Last Update
October 23 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Jacksonville, Florida, United States, 32224
2
Massachusetts General Hospital
Boston, Massachusetts, United States
3
Mayo Clinic
Rochester, Minnesota, United States